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The use of bacteriophages as antibacterial agents is being actively researched on a
global scale. Typically, the phages used are isolated from the wild by plating on the
bacteria of interest, and a far larger set of candidate phages is often available than can
be used in any application. When an excess of phages is available, how should the best
phages be identiﬁed? Here we consider phage-bacterial population dynamics as a basis
for evaluating and predicting phage success. A central question is whether the innate
dynamical properties of phages are the determinants of success, or instead, whether
extrinsic, indirect effects can be responsible. We address the dynamical perspective,
motivated in part by the absence of dynamics in previously suggested principles of phage
therapy. Current mathematical models of bacterial-phage dynamics do not capture the
realities of in vivo dynamics, nor is this likely to change, but they do give insight to qualitative
properties that may be generalizable. In particular, phage adsorption rate may be critical
to treatment success, so understanding the effects of the in vivo environment on host
availability may allow prediction of useful phages prior to in vivo experimentation. Principles
for predicting efﬁcacy may be derived by developing a greater understanding of the in vivo
system, or such principles could be determined empirically by comparing phages with
known differences in their dynamic properties.The comparative approach promises to be a
powerful method of discovering the key to phage success.We offer ﬁve recommendations
for future study: (i) compare phages differing in treatment efﬁcacy to identify the phage
properties associatedwith success, (ii) assay dynamics in vivo, (iii) understandmechanisms
of bacterial escape from phages, (iv) test phages in model infections that are relevant to
the intended clinical applications, and (v) develop new classes of models for phage growth
in spatially heterogeneous environments.
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INTRODUCTION
Phage therapy, long practiced in some countries, is enjoying a
rebirth in Western medicine (Gill, 2010; Abedon et al., 2011; Gill
and Young, 2011; Ryan et al., 2011; Tsonos et al., 2013a). As cur-
rently practiced, phage therapy seems to be a largely idiosyncratic
discipline, in that there are few fundamental principles that can
be defended or refuted with experimental validation, other than
the obvious ones of using phages that infect the offending bacteria
and applying a broad spectrum of phages simultaneously. Signiﬁ-
cant thought has been given to the rational design of phage-based
therapeutics (Gill and Hyman, 2010; Goodridge, 2010), but such
considerations are limited by our understanding of phage biol-
ogy and the in vivo realities of antimicrobial treatment. To date,
most of what can be said about the rational choice of a therapeu-
tic phage is related to its host range and the possibility of phage
resistance, and some practical considerations such as phage sta-
bility and ease of production. Other phage characteristics, such as
high adsorption rates, in vivo persistence, or high fecundity (short
latent periods and large burst sizes) are presumed to be beneﬁcial
but with little understanding as to what speciﬁc parameter values
are compatible with treatment success.
It may be that the only property required for efﬁcacy is a
phage’s ability to form plaques on a lawn of the infecting bac-
terial strain. If so, there will be little need for principles beyond
the determination of phage host ranges before deployment as
therapeutics. Ability to infect the target strain is obviously a nec-
essary condition, but it need not be sufﬁcient, and as the ﬁeld
has progressed, it has become apparent that not all phages are
equivalent in treating acute infections (Smith and Huggins, 1982;
Henry et al., 2013), and many studies of chronic infections reveal
that bacteria are not eliminated by phages, even though clinical
symptoms are often reduced (Scott et al., 2007; Hurley et al., 2008;
El-Shibiny et al., 2009; Tsonos et al., 2013b); treatment of plant
infections has also revealed efﬁcacy differences among phages
(Balogh et al., 2010). Even more problematic, the literature may
be biased toward phage therapy successes (Tsonos et al., 2013a),
obscuring the extent to which the type of phage or treatment
matters to the outcome.
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Evenwhen phages workwell at curing infections, little is known
about the phage-bacterial dynamic or what is needed for success.
This poor understanding complicates the development of phage
therapy as a science. There are no broad spectrum phages to rival
antibiotics: phage host ranges are too narrow, typically limited
to a subset of strains within a bacterial species. Although a nar-
row host range is often considered an advantage of phage therapy
over antibiotics, it does mean that many different phages will be
needed, and thus must be tested, to provide treatments effec-
tive against infections caused by different pathogens. The hope
is that there may be ‘broad spectrum properties’ of phages that
can be employed in choosing successful phages a priori with a
minimum of experimental failure. To do so requires understand-
ing what distinguishes successful phages from unsuccessful ones,
and why.
This paper is thus motivated by two premises. First, for many
types of infections, not all phages are equally effective at enabling
recovery. Second, we propose that there are properties of efﬁca-
cious phages that will generalize across different infections so that,
when those properties are known, they can be used to select phages
suitable for treatment.Whilewe review several properties that have
been proposed, this paper is equally about the search for principles
and methods that might be used in that search. As phage control
of bacteria is intrinsically one of population dynamics, we apply
that perspective. The paper combines a review of previous work
with a synthesis of existing models and observations and offers
recommendations for future studies.
PREVIOUSLY SUGGESTED PRINCIPLES
We begin with a list of principles that have been proposed to ben-
eﬁt treatment (Table 1). Rationales behind these principles have
been discussed elsewhere and so will not be covered in depth here
(references to previous works are provided in Table 1). While it
is obvious that a phage must be able to infect a bacterial strain to
be useful for treatment (thus it is not listed here), the other prin-
ciples have been practiced to varying degrees, with the majority
of phage therapy studies focusing on the ﬁrst two or three criteria
listed in Table 1. A principle may be widely acknowledged without
Table 1 | Suggested principles in the choice of phages for therapy.
Principle Benefits Drawbacks Reference
1 Broad host range Reduces need to diagnose infecting
strains; may simultaneously attack
multiple strains of a single pathogen
Broad host range may conﬂict with
other optimal phage characteristics
Balogh et al. (2010), Gill (2010)
2 Phage mixtures targeting
different host receptors
Development of resistance to
phage less likely as mutants
resistant to one phage remain
sensitive to others in the mixture
Greater development time, may limit
the repertoire of phage available for
some bacteria
Balogh et al. (2010), Gill (2010),
Chan and Abedon (2012), Chan
et al. (2013)
3 Non-temperate Avoids lysogeny as an easy form of
bacterial insensitivity; avoids
pathogenicity genes commonly
found in temperate phages
Limits the repertoire of phage available
for some bacteria
Gill andYoung (2011)
4 Ability to clear liquid cultures Simple in vitro assay Applicability to in vivo success
unknown
Smith and Huggins (1982),
Henry et al. (2013)
5 Non-lysing phages Cells are killed without releasing
toxins
Phage do not amplify, so huge numbers
of phage must be inoculated
Matsuda et al. (2005)
6 Target surface virulence
determinants or otherwise
impose high cost of resistance
Difﬁcult bacterial escape; resistant
cells become unﬁt/avirulent
Limits the repertoire of phage available Capparelli et al. (2010a,b),
Viertel et al. (2014), this paper
7 Tailspike de-polymerase Acapsular bacterial mutants are
often avirulent (see item 6);
unassembled tailspikes released at
lysis as free enzyme, digest capsule
of nearby cells and expose them to
immune system
Possibly limited host range of such
phage, limits the repertoire of phage
available for some bacteria
Francis et al. (1934),
Sutherland (1995), Mushtaq
et al. (2004), Malnoy et al.
(2005), Bull et al. (2010)
8 Non-transducing Will not mobilize pathogenicity or
antibiotic resistance determinants
Limits the repertoire of phage available
for some bacteria
Gill (2010)
9 Slow in vivo virion decay rate Increases phage longevity in the
animal host, increasing probability
of phage encountering bacteria
None obvious, may allow for faster
development of acquired immunity to
phage
Merril et al. (1996), Balogh
et al. (2010)
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being widely implemented (e.g., avoidance of temperate phages is
widely appreciated, but phages are rarely rigorously conﬁrmed to
be obligately lytic before use).
Advantages of several of these principles are not obviously rel-
evant across all therapeutic applications. The ability to clear liquid
cultures or other indicators of in vitro growth have been reported
as a positive indicator of success in some cases (Smith and Hug-
gins, 1982; Henry et al., 2013), but not in others (Balogh et al.,
2010; Tsonos et al., 2013b); without a mechanistic link between
in vivo and in vitro growth, this assay is not a guarantee of suc-
cess. Many of the principles proposed have no obvious downside
beyond practical considerations of ﬁnding phages with the desired
characteristics, but how crucial each characteristic is for treatment
success is far from being resolved. For example, phage targeting
of surface virulence determinants is probably an advantage, but
there are many reports of treatment success using phages that do
not seem to speciﬁcally target receptors critical to virulence (e.g.,
Merril et al., 1996; Matsuzaki et al., 2003; Atterbury et al., 2007)
so this criterion is apparently not an absolute requirement for
success.
These suggested principles are surprisingly devoid of dynamical
considerations, other than the obvious one that the phage must be
able to grow on the infecting strain. Principle 4 (the ability to clear
liquid cultures) is the closest exception, although the outcome
of this type of assay is the product of several individual dynamic
parameters. This omission of suggested dynamical principles leads
to an important question, considered next.
THE CENTRAL QUESTION: HOW IMPORTANT ARE DYNAMICS
TO TREATMENT SUCCESS?
In the search for successful phages, it is important to knowwhether
a phage’s success is tied closely to its intrinsic dynamical proper-
ties: what are the relationships between phage replication rates,
the rate of phage killing of the bacterial population and the proba-
bility of treatment success? It is probably generally true that phage
success requires a minimum level of growth on the target popu-
lation, but beyond that minimal requirement, does incrementally
better phage growth lead to enhanced success? Indeed, the paucity
of population dynamics principles in Table 1 raises the possibility
that dynamic principles are not important to phage therapy success
(alternatively, dynamics may have not been studied). Determining
whether and under what conditions phage growth and host killing
correlate with success – and how they contribute – should be a
goal of the phage therapy enterprise. This paper thus considers
what we know about the relationship between phage dynamics
and bacterial control as well as how that relationship may be
assessed.
MATHEMATICAL MODELS OF DYNAMICS
On a qualitative level, we know that phage growth depends
on bacterial numbers. Yet phage growth reduces bacterial num-
bers, and this bacterial decline feeds back by reducing future
phage numbers. It is thus easily appreciated that the quantitative
dynamics of the phage-host interaction are too complicated for
intuition, motivating the use of mathematical models. Mathemat-
ical models of dynamics can potentially serve multiple purposes,
from merely guiding intuition, to yielding qualitative results
that can be evaluated empirically, to providing a quantitative
ﬁt to empirical data. We begin by reviewing the models that
have been proposed and how they may be used to understand
dynamics.
The long history of pharmacodynamic and kinetic studies of
antibiotics andbacteria inspired parallelmodels of phage-bacterial
infection dynamics with the speciﬁc goal of understanding in vivo
processes; the efforts are still few (Levin and Bull, 1996, 2004;
Payne and Jansen, 2001, 2003; Weld et al., 2004; Bull and Regoes,
2006; Abedon, 2011, 2012). Levin and Bull (2004, 1996) addressed
dynamics at high bacterial densities, when phages proliferate,
whereas Payne and Jansen (2001, 2003) emphasized dynamics
when bacterial densities are low or when phage may otherwise
be unable to maintain themselves. Those models of in vivo phage
dynamics are little more than standard models of in vitro dynam-
ics, with the usual assumptions of mass action (diffusion in liquid)
and spatial plus temporal homogeneity of parameters and pro-
cesses (see Levin and Bull, 1996; Weld et al., 2004; Bull and
Regoes, 2006; Abedon, 2012 for some exceptions). Phage growth
in liquid is determined by three parameters, the adsorption rate
constant, burst size, and lysis time or latent period (Table 2).
A homogeneous culture of one phage type (density P) attack-
ing one bacterial type (density B) is described by two differential
equations:
dB/dt = αB − kPB − δB (1)
dP/dt = bkPLBL − kPB − δP (2)
(e.g., Adams, 1959; Campbell, 1961), with notation given in
Table 2. dB/dt and dP/dt are rates of change with time of bac-
terial and phage densities; variables subscripted with L indicate
the value of that variable L minutes in the past. Payne and
Jansen (2001) added terms for time-dependent decay rates due
to host response but essentially ignored those terms in their anal-
yses, reﬂecting the difﬁculty in empirical determination of these
values.
The chief unintuitive process in these equations is adsorp-
tion (attachment of the virion to the bacterium), which proceeds
according to second-order reaction kinetics. At a mathematical
level, adsorption combines the two processes of virion attach-
ment to the cell and actual infection of the cell; any delay between
phage attachment and genome entry is trivially subsumed into
lysis time. The adsorption rate constant, k, itself combines two
processes: (i) the rate of chance encounter by diffusion of a single
Table 2 | Parameter definitions.
Notation Description Units
α Growth rate of uninfected bacteria /min
b Burst size: number of phage progeny released at
lysis
PFU
k Phage adsorption rate constant mL/min
L Time to host cell lysis after phage infection min
δ Death or removal rate /min
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phage particle with a single bacterium in 1 mL of liquid with (ii)
the rate at which the phage initiates an infection (adsorbs) given
an encounter. Because of (i), empirical values of k are always low –
10−8 mL/min or less – reﬂecting the low rate of chance encounter.
Values of k much below this approximate limit typically stem from
low rates of infection given an encounter. Detailed empirical analy-
ses suggest that infectionoften follows a 2-stepprocess of reversible
adsorption followed by irreversible adsorption (Adams, 1959;
Moldovan et al., 2007); the effect of this complication on dynam-
ics has not been modeled but is likely accommodated to a suitable
approximation with the standard model. The interrelationships
between phage density, bacterial density and k will be discussed
only in general terms here, as they have been examined exten-
sively elsewhere (e.g., Levin and Bull, 1996; Payne and Jansen,
2001; Gill, 2008; Abedon and Thomas-Abedon, 2010; Abedon,
2011).
By virtue of the deterministic nature of the equations, bacteria
are never strictly eliminated in these models – even if the density
drops below 1/unit volume, phage are modeled as if present in
inﬁnite volumes. Furthermore, phage parameters are constant, so
any phage that increases initially will ultimately outgrow bacte-
ria in this model, leading either to a joint equilibrium of phage
and bacteria or continual oscillations (Levin et al., 1977). There
is thus no intrinsic property of the dynamical equilibrium that
can be used to infer host survival or death. Host mortality has
been equated with bacterial density reaching a threshold at any
point in the infection (Levin and Bull, 1996), or with persistence
of the bacterial population beyond a set period of time (Payne and
Jansen, 2001). By this criterion of treatment success, faster growth
of a phage – better phage fecundity per unit time – always increases
treatment superiority. Thus, if the model indeed represents reality,
wewould readily conclude that phage dynamics directly determine
treatment success.
THE MODELS DO NOT QUANTITATIVELY DESCRIBE REAL INFECTIONS
There are two serious difﬁculties in using parameterized mod-
els as quantitative predictors of real infections. Most importantly,
the models are poor characterizations of infections – they neglect
inhomogeneous diffusion, host immunity, and time-varying and
space-varying parameter values (e.g., Payne and Jansen, 2003).
As noted above, the fate of the host is imposed artiﬁcially. Some
of these omissions can be incorporated easily, but many cannot.
Thus even if one could parameterize the models with average
parameter values, model utility is dubious. Second, parameter-
izing even the simple models in vivo can be a hopeless task. Weld
et al. (2004) showed equations of the sort described above were
unable to predict the quantitative interactions between phage T4
and Escherichia coli in the mouse gut. Thus the models are more
appropriately used for qualitative behaviors that we may hope
apply broadly.
The extent of model incompleteness is easily comprehended
by considering just the speciﬁc empirical realm of phage access
and delivery to bacteria. Phages may be applied in vivo at very
high doses, with MOIs of ten or more based on total bacte-
rial counts of infected tissue. Yet it is rarely if ever known how
many of these phage actually reach a bacterium; that is, the in
vivo values of P and k are not known and are probably highly
heterogeneous within the same animal. Several factors may reduce
the number of phage encountering hosts in vivo, including par-
tial or complete spatial refuges and rapid clearance of phage
by passive or active immunity, or exposure to UV light in the
case of plant applications (Balogh et al., 2010). Physical prop-
erties of the virion such as surface charge, hydrophilicity, and
physical dimensions may affect its ability to penetrate physi-
cal refuges, and thus affect the functional in vivo adsorption
rate. It has been observed that bacterial growth status can have
a signiﬁcant effect on all three of the major model parame-
ters: starved E. coli cells exhibit lower adsorption rates, longer
latent periods, and reduced burst sizes when exposed to phage
T4 than cells grown in rich medium (Hadas et al., 1997). Thus
the physiology of the bacterial cells is an important considera-
tion when attempting to predict the efﬁcacy of a phage treatment.
Phage have also been shown to interact with the in vivo envi-
ronment, such as with mucus present in the human intestine
(Barr et al., 2013). In the context of phage treatment of gastroin-
testinal infections, this phenomenon could prove to be a barrier
to exogenously introduced phage by retarding phage diffusion,
or could be a beneﬁt by maintaining high local concentrations
of phage at the mucosal surface. These complexities provide a
mere glimpse of the challenges in developing accurate models of
infection dynamics.
EXISTING MODELS DISPLAY UNINTUITIVE BEHAVIORS THAT MAY
QUALITATIVELY DESCRIBE INFECTIONS
Although existing models are not accurate descriptors of in vivo
systems, they can be useful in identifying dynamical behaviors
that are potentially observable in infections at a qualitative level.
There are of course obvious inferences from the models – larger
burst and adsorption rates or shorter lysis times are always bene-
ﬁcial when considered in isolation. Also, the dynamics of bacterial
killing depend both on the inoculum dose and subsequent phage
replication; a sufﬁciently large phage inoculum can reduce bacte-
rial numbers below a threshold without any phage reproduction at
all – the ‘passive’ therapy of Payne and Jansen (2001); use of large
inoculum doses may help in many applications where bacterial
densities are low or phage exhibit poor growth (Bull and Regoes,
2006).
Some dynamic properties are less obvious. We describe three
examples that may facilitate choosing phages for therapy and
diagnosing the causes of failure.
Bacteria and phage can be maintained at high densities when
adsorption rate is low
As illustrated in Figure 1, the adsorption rate constant (k) has a
major effect on the equilibrium densities of both bacteria and
phage (at least in systems with constant ﬂow or death rates;
Levin et al., 1977). High values of k – those near 10−8 mL/min
or higher – enable phage to suppress bacterial densities to low
levels. Values of k that are 2–3 logs lower relax phage control of
bacteria, resulting in an equilibrium at which both bacteria and
phage are abundant (Levin et al., 1977). Although those bacteria
are technically sensitive to phage, and phage do indeed replicate
on the bacteria, bacterial densities are only minimally impacted
by phage at the time scales typically under consideration. Note
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FIGURE 1 | Co-dynamics of bacteria and phage in a model with a
constant washout rate. (A) shows dynamics with an adsorption rate of
10−9 mL/min, (B) with an adsorption rate of 10−10 mL/min. Parameters
are otherwise the same between (A) and (B). The higher adsorption leads
to better killing of the cells. As is typical in these models when adsorption
rate is high, densities ﬂuctuate because phage decline (due to washout)
after cell density has been depressed, and once phage density declines,
bacterial densities rebound until phage catch up. However, with a mere
10-fold decline in adsorption rate, phage can grow but fail to depress
bacterial densities substantially. The model is based on differential
equations similar to those in Bull et al. (2014).
that this process is fundamentally different than the failure of
phage to control bacteria due to low bacterial density identiﬁed
by Payne and Jansen (2001). In an infection, the high phage den-
sity might give the impression that phage were having a large
effect, but the high bacterial density would belie that interpre-
tation. Thus this model property could help resolve a common
empirical paradox.
Adsorption rates may not be homogeneous in a bacterial population
This point rests on the previous one and can be modeled with a
simple extension of equation (1), in which the starting bacterial
population contains a subpopulation with a lower but non-zero
adsorption rate (Figure 2). When phage are ﬁrst introduced to
the naïve bacterial population, their dynamics are dominated by
the average adsorption rate. However, as phage become common,
individual bacteria with high adsorption rates are killed fastest;
those with low rates are killed slower. The composition of the sur-
viving population is quickly converted to one of bacteria with the
lowest adsorption rate, and if that rate is low enough, phage may
fail to control bacteria even though those bacteria are genetically
sensitive (Bull et al., 2014). A genetically uniform population of
bacteria may exhibit quantitative variation in the adsorption rate
of individual cells, either by inhabiting protected sites inaccessible
to the phage or by exhibiting quantitative ‘phenotypic’ resistance.
The effects of phenotypic resistance and physical refuges are sim-
ilar – both mechanisms enable a subset of bacteria to escape
control by phages – but there is no physical structure associ-
ated with phenotypic resistance. This principle can also apply to
infections spanning multiple tissues: phage growth can be at the
expense of bacteria in some infected tissues, while the bacteria in
other tissues escape control. Selection for phenotypic resistance
directly parallels the selection for genetically resistant organisms,
FIGURE 2 | Co-dynamics of bacteria and phage. In contrast to Figure 1,
here the population consists of a mix of cell types differing only in
adsorption rate (10−9 or 10−10 mL/min). Initially, there is a 50-fold excess
of cells with the higher adsorption rate, but there is a low rate at which
each cell type is converted into the other. The phage ascends rapidly
because most of the cell population has a high adsorption rate. However,
bacterial densities are only mildly affected because the low-adsorption
population displaces the high adsorption rate population. The result is
paradoxical because the phage population ascends as if it will kill well, yet
bacterial densities show only a slight depression; similar dynamics are seen
in the case of a subpopulation of cells occupying spatial refuges. The model
in this ﬁgure corresponds to the ‘intrinsic’ phenotypic resistance model in
Bull et al. (2014). Parameters are otherwise the same as in Figure 1.
but because phenotypic resistance may be a physiological adap-
tation and offers only partial resistance, it may occur at much
higher frequency in naïve bacterial populations and have little cost
to the bacterium. Phenotypic resistance thus offers an immedi-
ate response to phage attack that has a high potential to thwart
treatment.
Parameter values affecting treatment success are interrelated
Adsorption rate properties have obvious ramiﬁcations for treat-
ment that can be identiﬁed from the models. Can we infer other
dynamical determinants of success versus failure? Burst size and
latent period certainly affect phage growth, although there are
wide, biologically relevant latitudes in these parameter values that
still allow treatment success in the standard models. In mod-
els of inundative or passive therapy, parameters of latent period
and burst size are largely irrelevant, as the entire interaction is
governed by the adsorption process. In models of active ther-
apy however, where phage replication is required for success,
extremely long latent periods or very low burst sizes can neg-
atively affect predicted efﬁcacy. Furthermore, a decline in one
parameter may be offset by gains in the others, such that lower
adsorption rates could be compensated for by increased burst sizes,
and so on.
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SUMMARY: THE IMPORTANCE OF DYNAMICS AS DESCRIBED BY
MODELS
Mathematical models of phage bacterial dynamics thus far fail to
capture the detailed properties of in vivo treatment. The abstract
models nonetheless help us understand dynamical properties that
may apply in vivo – properties that may underlie phage failure. We
can hypothesize that phages with greater adsorption rates, larger
burst sizes and shorter latent periods will exhibit superior per-
formance, but it is still not known how the in vivo environment
affects these parameters. It is probably true that they are lower
in vivo than in vitro measurements would suggest, but this is an
area in signiﬁcant need of study. The rate at which phage adsorb to
bacteria is very likely to be a key factor in determining treatment
success, and quantitative differences in adsorption rate can be a
subtle determinant of phage success versus failure. The importance
of individual aspects of phage dynamics to treatment success has
not been established empirically, and we can further hypothesize
that at least a qualitative understanding of those properties will
aid in the selection of more effective phages. Evolution is another
obvious dimension to consider, especially the evolution of bac-
terial escape. This is, however, a process on a longer time scale
than the dynamics considered in this paper. Bacterial evolution
could be an important mechanism of therapy failure and justiﬁes
a serious investigation.
EMPIRICAL DYNAMICS
The preceding section described a ‘models forward’ approach to
dynamics, in which the models have attempted to describe the
mechanisms of different treatment outcomes, an approach which
has had very limited success to date. Alternatively, phage dynamics
can be measured in vivo ﬁrst and then simple models could be
developed to interpret the data.
MEASURING DYNAMICS DIRECTLY
Ideally, we would like to know the bacterial and phage densities
through time at all sites in the host. In reality, our options are
not nearly this sophisticated, but they are continually improv-
ing. Various methods for in vivo determination of dynamics may
be feasible, such as time courses of bacterial and phage num-
bers (Smith and Huggins, 1982; Weld et al., 2004; Scott et al.,
2007; Hurley et al., 2008; El-Shibiny et al., 2009); new imag-
ing methods allow the partial study of dynamics non-invasively
(Contag, 2008; Barman et al., 2011; Henry et al., 2013). Alterna-
tively andmore simply, short-term,whole-organismphage growth
rate may be measured (Bull et al., 2012). In all these methods, one
is observing the dynamical outcomes that would be predicted by
an appropriately parameterized model but doing so without the
underlyingmodel. This approach is especially practical for chronic
infections where bacterial and phage counts can be monitored
non-invasively, as with surface and gastro-intestinal infections and
environmental treatments. It does not necessarily provide the same
insight to mechanisms as would parameterization of a model, but
with modest effort, it may be possible to ﬁt models to the observed
dynamics.
Central to any such effort is the choice of an appropriate
dynamic property. Maximum phage growth rate, maximum bac-
terial density, total bacteria lysed, phage fecundity per infection
event, and countless others are possible. However, it is not yet
clear which particular properties are most relevant in any given
infection system. For example, Bull et al. (2012) used 6 h dynam-
ics to infer that each of two types of phages possessed dynamic
properties suitable for numerically overwhelming the bacterial
population, yet one of the phages failed to control the infection,
suggesting that, in this system at least, this dynamic property
(bulk phage replication) was not a determinant of treatment
success.
Once a dynamic property has been chosen, the empirical data
may be used in at least two different ways. As with the example
given immediately above, the dynamic data can be used quan-
titatively, to decide whether a dynamic process or outcome is
compatible with the data. Here, the data are in essence being
ﬁt to a perhaps crude but quantitative model. A second use is
comparative and requires that multiple phages have been com-
pared both for dynamics and for treatment success. One may
then consider whether dynamical properties correlate with treat-
ment success. Here, the data are not being ﬁt to any dynamical
process, only compared internally, among different phages. Such
a comparison might show, for example, that phages with faster
in vivo growth rates are superior in treatment. This comparison
does not establish that growth rate is the cause of success or fail-
ure (e.g., Bull et al., 2010) or even that the growth rate of any
phage is dynamically compatible with controlling the infection.
But if such a comparison showed that phages with slower in vivo
growth rate were superior in treatment, it could be concluded
that this dynamical superiority was not the cause of treatment
success.
If dynamics over time are not attainable, bacterial and phage
counts at a single time after treatment may be informative, pro-
vided the time of assay is chosen appropriately. An approach as
simple as merely dichotomizing the densities into ‘high’ and ‘low’
categories may yield considerable insight to phage quality and to
the possible causes of failure (Table 3).
The value of counts for discriminating phages may depend
heavily on the details obtained in the assays. Tissue speciﬁc
counts will be more useful than whole body counts. Prior studies
notwithstanding, this approach to phage therapy remains largely
undeveloped as a tool for understanding success versus failure.
COMPETITIONS: A CONVENIENT MEASURE OF RELATIVE DYNAMICS
Use of multiple phages in a treatment will nearly always result in
some phages outgrowing others, provided that some of them do
indeed grow. Changes in the abundances of the different phages
provides a relative measure of phage dynamics that may be used
to infer which phages perform best. Competitions are in fact sim-
ple dynamical assays measured on a relative scale. This method
can be used on a potentially large set of inoculated phages as a
way of sorting out the ‘best’ ones, reducing the number of tri-
als that must be conducted. The determination of competitive
ability is now greatly facilitated by the availability of inexpensive
quantitative PCR and DNA sequencing technologies. The main
drawback of competitions is that interactions among phages may
alter the dynamics so that the relative growth rates do not reﬂect
growth rates in isolation (Adams, 1959; Bull et al., 2006, 2012).
This caution notwithstanding, the method is easy and could lead
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy November 2014 | Volume 5 | Article 618 | 6
Bull and Gill Phage properties for effective therapy
Table 3 | Interpretation of bacterial and phage counts at a single time point after treatment.
Phage density Bacterial density Implication
High High Low adsorption rate or partial bacterial refuge, poor control of bacteria. Gives insight to failure
High Low Not sustainable – a possible transitory step following successful control of bacteria, before phage densities have
equilibrated
Low High Phage unable to replicate adequately; possible genetic resistance of bacteria or inaccessible refuge
Low Low Treatment success
to useful insights. Furthermore, the competitive dynamics may
reveal interactions that can be useful for or inimical to treatment
when cocktails are applied.
SUMMARY OF EMPIRICAL DYNAMICS
Although mathematical models do not capture many in vivo real-
ities, dynamics may be measured empirically and give insight to
mechanismsunderlyingphage treatment. Themajor limitations to
this approach are largely technical, requiring the ability to observe
the phage and their hosts at high spatial and temporal resolutions.
Even when the dynamics can be measured, it is still not trivial to
establish how dynamics contribute to treatment outcome: phages
with superior dynamics may be superior at treatment for reasons
other thandynamics. Despite theseunknowns, theuse of dynamics
to understand outcomes is worthy of investigation.
INDIRECT EFFECTS: ALTERNATIVE PATHS TO EFFICACY
We have raised the possibility that phage dynamical properties
may not be the main determinant of treatment success. Yet aside
from the principles listed in Table 1, alternatives to phage suc-
cess have not been offered. Indirect effects of phages provide one
such alternative. Indirect effects are phage-caused modiﬁcations
of the environment that alter bacterial dynamics or alter the host
response; they can be considered effects of a phage that extend
beyond burst size, lysis time, and adsorption rate. We offer three
diverse examples.
THE IMMUNE RESPONSE AFFECTS OUTCOME
As a rule, phage do not fully clear large bacterial populations
on their own, they merely reduce bacterial numbers. The com-
plete clearing of an infection by phage must thus rest with the
immune system, and phages may differ in how they affect immu-
nity. Phage-encoded depolymerase enzymes can be sufﬁcient to
cure an infection (Avery and Dubos, 1931; Francis et al., 1934;
Sutherland, 1995; Mushtaq et al., 2004); such enzymes presumably
expose bacteria to constitutive immune defenses by stripping away
capsules andother protective layers on the bacterial surface (Mush-
taq et al., 2004; Scholl et al., 2005). Depolymerases are observed as
components of phage tailspike assemblies, and a signiﬁcant pro-
portion of these tailspikes are thought to be released unassembled
as free enzyme upon cell lysis. Thus phages with those enzymes
both kill bacteria and help the immune system kill the bacteria
that phage miss. This indirect effect improves treatment.
A second suggestion of the importance of immunity comes
from a study showing that the physical lysis of bacteria worsens
treatment outcome, presumably because lysis releases endotoxins
(Hagens et al., 2004; Matsuda et al., 2005; Paul et al., 2011). In this
case, the indirect effect of the phage— the release of endotoxins—
hampers treatment.
Finally, bioﬁlms may present barriers to phage access; the
exopolysaccharide matrix (EPS) is considered to be one such
barrier. Phages that produce enzymes degrading the EPS are
thought to impart improved bioﬁlm clearing over phages lacking
such enzymes because the enzymes destroy the physical struc-
ture of the bioﬁlm (Hughes et al., 1998; Azeredo and Sutherland,
2008). Futhermore, phages may even be engineered to express
bioﬁlm-degrading enzymes that improve bioﬁlm clearing (Lu and
Collins, 2007). Although these enzymes may have the effect of
exposing greater numbers of bacteria to phage killing, enzyme
has been shown to be sufﬁcient for bioﬁlm clearing in the
absence of phage (Schmerer et al., 2014), thus indicating an indi-
rect effect of the engineered phage. This example parallels that
above of capsular depolymerases enhancing immune clearing of
bacteria.
DIAGNOSING INDIRECT EFFECTS
Indirect effects present a distinct contrast to the model that
treatment success stems from phage dynamics. They thus offer
an important avenue for study, but it is not trivial to demon-
strate indirect effects, because they will usually be confounded
by dynamics. In the three examples cited above, indirect effects
were evident because a manipulation enabled treatments that
changed the balance between dynamics and indirect effects (a non-
lysing phage that improved survival, treatment with an enzyme
alone improved the outcome). Genome engineering and the
generation of isogenic phage variants will provide one fruitful
avenue to explore a wide range of possible direct and indirect
effects.
SUMMARY OF INDIRECT EFFECTS
There are sporadic demonstrations in which treatment success
does not result directly from rampant phage killing, and these
indirect effects offer a distinct alternative to dynamics as the basis
of phage therapy success. There is already evidence that they are
important in some systems. The degree to which they inﬂuence
treatment success will have a major effect on the rational choice of
phages for treatment.
COMPARATIVE METHODS CAN IDENTIFY CAUSES OF PHAGE
SUCCESS
The focus of this paper has been the ‘Central Question’ on the
importance of phage dynamics to therapeutic success. On the
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surface, the path to answering this question would seem to be the
direct approach of quantifying phage dynamics and determining
whether they can explain treatment outcome. This direct approach
is difﬁcult at least because the cause–effect relationships are not
obvious from dynamics alone, and many types of experimen-
tal manipulations are required to establish whether quantitative
properties of growth per se affect treatment outcome.
An alternative, powerful approach to identifying causes of
treatment success is the comparative method (Pagel and Har-
vey, 1988; Harvey and Purvis, 1991): characteristics of phages
with high success rates are compared to characteristics of phages
with low success rates. Characteristics differing between the two
groups become candidates for causation. The characteristics con-
sidered might be genetic or lifestyle characteristics (e.g., receptor
type, DNA ejection and host-takeover mechanisms) as well as
various gross phenotypes (e.g., growth rate, virion size, virion
charge). Among other applications, the comparative method can
be used to determine if treatment success correlates with dynamic
properties.
Applications of the comparative method to phage therapy are
surprisingly rare in the literature, as there are few studies meet-
ing its minimum requirement: identiﬁcation of both effective and
ineffective phages for the same infection model. The classic com-
parative study is by Smith and Huggins (1982) using mice infected
with E. coli O18:K1:H7. Across a set of wild phages, those requir-
ing the bacterial capsule were invariably more effective at saving
mice (at least when treatment was administered concurrently with
bacteria), whereas those using a different receptor were invariably
poor. In a second more recent example, a panel of Pseudomonas
aeruginosa phages was evaluated both in vitro and in vivo in a
mouse infection model (Henry et al., 2013). In the latter case,
simple plaque-forming ability (measured as EOP) was found to
be a poor predictor of therapeutic efﬁcacy, while the ability of
the phage to clear liquid cultures was a better but still imperfect
predictor. Phages isolated from the environment on the mouse
challenge strains were found to be more effective in treatment,
but what speciﬁc phage attributes were key to therapeutic suc-
cess remains to be determined. Differences in phage efﬁcacy have
also been reported in treatment of plant infections (Balogh et al.,
2010).
The challengewith the comparativemethod is to identify causal
characteristics, not just correlates. Causation can be inferred when
there is only a single variable responsible for the correlation (when
all but one variable is controlled for in the comparison). For
example, in the case of Merril et al. (1996), the effective and less
effective phages were isogenic except for a point mutation in the
capsid protein gene, thatmutationnecessarily being causal. For the
capsule-dependent and -independent phages of E. coli O18:K1:H7
in the Smith-Huggins mouse model, the endosialidase tailspike
was identiﬁed as the critical determinant of treatment success
because the only signiﬁcant genetic difference between one pair of
phages was that gene (Bull et al., 2010). Conversely, when the effec-
tive and ineffective phages differ in multiple characteristics, as in
the case of Henry et al. (2013), itmay not be possible to identify the
crucial difference without some form of genetic manipulation to
experimentally alter thephage genome. However, to assesswhether
dynamic properties determine success, an attainable initial step is
merely to compare dynamic qualities between the two classes of
phages.
SUMMARY OF COMPARATIVE STUDIES
The comparative method offers a fast approach to identifying cor-
relates of treatment success. There are yet few applications of the
comparative method to identify the basis of phage success versus
failure, no doubt because there are few systems that have identiﬁed
parallel sets of phages with high and low efﬁcacy. This is perhaps
the most promising avenue to pursue in resolving the basis of
treatment success.
FUTURE DIRECTIONS
Phage therapy need not be conﬁned to the practices used in the
past. Phages may be combined with other treatments or may be
engineered with properties that do not occur naturally.
ADSORPTION RATE AND INSIGHTS TO IMPROVED THERAPY
The qualitative behaviors inferred from the models provide guid-
ance toward possiblemechanisms of phage failure and thus toward
ways to choose better phages. They ﬁrst suggest that it is notmerely
sufﬁcient to isolate phages that form plaques on the target bac-
terium or grow well when ﬁrst introduced into its populations:
those criteria do not avoid phages that are susceptible to escape by
cryptic bacterial mechanisms. These principles do suggest courses
of action: if phage do not control bacteria in vivo, escaping bacte-
ria should be checked for genetic resistance to the phages. Lack of
genetic resistance suggests an access problem – phenotypic resis-
tance or refuges. Some kinds of phenotypic resistance may be
overcome by use of phage that are able to bypass this phenotype.
Depending on their nature, physical refuges may pose a problem
to many types of phage, and may be circumvented by use of more
persistent or better-penetrating phage strains, or by using different
routes of administration. Finally, because the physiological state
of the bacterium can strongly affect subsequent phage dynamics,
there must be a greater understanding of the in vivo status of the
pathogen and how this affects the ability of the phage to infect and
replicate in its host. Ultimately, there is a need to identify classes
of bacterial escape mechanisms to devise strategies to thwart bac-
terial escape. We might hope that in vitro assays of phage-bacterial
dynamics can be used to identify phages worthy of in vivo testing,
but it may also be that useful identiﬁers of phage efﬁcacy await the
generation of a large database of correlations between in vitro and
in vivo dynamics.
Our current understanding leads us to suggest that there may
be classes of bacterial surface molecules that, when used by phages
for adsorption, are not prone to bacterial escape by refuges or phe-
notypic resistance. Capsules constitute an obvious target fulﬁlling
this criterion, because capsules are typically dense enough that the
bacterium may not be able to simultaneously reduce adsorption
by a phage targeting the capsule and also avoid immune attack. We
hypothesize that it should be possible to identify types of bacte-
rial surface molecules that avoid non-genetic bacterial escape and
to then use that knowledge to choose phages a priori for ther-
apy. It is too early to know if that knowledge can be generated
from in vitro data. However, this hypothesis is consistent with the
common observation that capsular depolymerases improve phage
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treatment success both in vivo and in bioﬁlms (Sutherland, 1995;
Azeredo and Sutherland, 2008). A systematic study of phage recep-
tors and quantitative bacterial escape may reveal several types of
phage targets that avoid or reduce bacterial escape, with capsules
being just one. A ﬁrst step toward this goal is to study dynamics
in vitro (in vivo, if possible) and observe the details of bacterial
decay and recovery in the presence of phage. Phages that have
better properties at depressing bacterial densities and maintaining
low densities should be candidates for application.
COMBINATIONS OF PHAGES AND ANTIBIOTICS
A long-touted beneﬁt of phages is that they can grow on antibiotic
resistant strains of bacteria: the genetic bases of drug resistance
rarely prevent phage growth. However, a less obvious tie between
phages and antibiotics is that they may complement each other in
treatment, both being more effective in combination than either is
alone. A practical utility of studying phage therapy during antibi-
otic treatment is that clinical trials often require the testing of new
treatments in a background of standard treatment — antibiotics.
Even when a bacterium is sensitive to an antibiotic and a phage,
treatment with either alone often results in a subset of bacteria that
avoid killing. Several reports now reveal greater bacterial killing
when phage and antibiotics are used in combination than with
treatment by either alone (Huff et al., 2004; Bedi et al., 2009;Verma
et al., 2009, 2010; Rahman et al., 2011; Chhibber et al., 2013;Viertel
et al., 2014). This ‘synergy’ is typically quantitative, not absolute,
so many bacteria escape the combined treatments. The dynami-
cal beneﬁt from combined treatment has not been investigated; it
must ultimately be that each agent kills subpopulations escaping
the other agent. Understanding and comparing the basis of escape
with single and double treatment should contribute to under-
standing phage therapy in the absence of drugs. Merely identifying
whether the best phages in combination with drugs are also the
best phages when used alone should lead toward an understanding
the basis of phage success.
ENGINEERED PHAGES
Advances in DNA synthesis and genomics will enable the facile
genetic engineering of phages. Most importantly, phages may
now be endowed with genes and phenotypes that would never
be observed in nature. Some of these modiﬁcations may be of
diagnostic value (e.g., Schoﬁeld et al., 2013; Peng et al., 2014),
others may be useful in treatment (e.g., Lu and Collins, 2007).
These modiﬁcations include using phages as chemical delivery
agents, using phages to change the bacterial genome, expanding
phage host range, blocking phage reproduction, encoding phages
with enzymes that degrade extracellular matrices, and others (e.g.,
Westwater et al., 2003; Lu and Collins, 2007, 2009; reviewed in
Viertel et al., 2014). The dynamical impacts may be to improve
phage growth, create/alter indirect effects, or even to modify bac-
terial competitiveness. As noted above, phage engineering may
greatly advance the study of both dynamics and indirect effects,
as these engineering methods should also provide tools for gen-
erating the deﬁned isogenic phage variants that can be used for
comparative in vivo or in vitro studies.
Success is not assured by the mere engineering of a desired phe-
notype. Success will also rest on dynamical issues—the engineered
phenotype must be of sufﬁcient magnitude and the phage density
must attain sufﬁcient levels to impact treatment. Dynamic anal-
ysis of the therapeutic failure of an engineered phage may thus
suggest ways to render it successful. However, a further impedi-
ment to the success of engineered phages is short-term evolution:
phage reproduction during treatment may reverse the engineer-
ing (Gladstone et al., 2012). Phages engineered to provide indirect
effects that do not beneﬁt phage growth will be especially prone
to evolutionary reversal, but engineering that beneﬁts phage pop-
ulation dynamics without speciﬁcally beneﬁtting the engineered
genome is also prone to reversal (Gladstone et al., 2012). Fortu-
nately, there is a simple solution to evolutionary reversal: repeated
inoculationswithhighdoses of the engineeredphage shouldmain-
tain moderate levels of the engineered phage despite opposing
evolution.
The potential of engineering extends well outside traditional
bounds of phage therapy. Temperate phages have been engineered
to render drug-resistant bacteria sensitive to antibiotics without
killing them (Edgar et al., 2012). This approach may at ﬁrst sight
seemuseless—the phagemight just aswell kill the bacteria asmod-
ify it. But the ecological effect of changing the bacterial genome
is to alter competition with drug-resistant bacteria in the exter-
nal environment, thus reducing the frequency of drug resistance
before an infection starts. The success of such an intervention is
obviously sensitive to many ecological and dynamical details, but
the work at least serves as an inspiration for many non-traditional
uses of engineered phages – and further highlights the possible
relevance of dynamics to success.
RECOMMENDATIONS
We suggest that the science of phage therapy will be advanced
by discovering principles that improve success, and the hope is
that principles from one system will apply to others. We offer the
following recommendations that highlight some of the preceding
points.
COMPARE THE GOOD AND THE BAD
Contrast therapeutically effective and ineffective phages to iden-
tify the causes of treatment success and/or failure. To apply the
comparative method, different phages must have been tested in
the same infection model, and some phages must yield bet-
ter treatment outcomes than the others. This approach can be
used regardless of the mechanism responsible for treatment suc-
cess/failure. The comparative approach has identiﬁed capsular
depolymerases as the basis of treatment success in one system;
rather than relying on the natural occurrence of convenient phage
pairs, the further development of genetic tools to create targeted
gene deletions or replacements in virulent phage will facilitate
direct comparisons of isogenic phage pairs.
EXPLORE AND CONSIDER DYNAMICS
A phage’s ability to grow in vivo is central to our understanding
of treatment outcome. Dynamics need not be the determinants
of success, but the relative contribution of dynamics to treatment
success needs to be understood. At present, it is practical to study
dynamics only qualitatively or in competitions, but even crude
assessments may pay off. Furthermore, study of dynamics can
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be coupled with the study of indirect effects to assess whether
dynamics is the key determinant of success.
UNDERSTAND BACTERIAL ESCAPE
Phage killing will often be only partial, with some bacteria escap-
ing. In turn, treatment outcome can depend on the quantitative
details of escape. Mutational resistance is a commonly cited
mechanism of bacterial escape but there are several other, less-
understood mechanisms such as transient phenotypic changes
and physical refuges that warrant consideration. Understanding
mechanisms of bacterial escape may thus prove valuable in choos-
ing appropriate phages, for example by avoiding types of receptors
that are prone to variation in the bacterial population or by using
phages that degrade exopolysaccharide matrices. Pathogen escape
in spatial refuges may be circumvented by altering the route of
phage administration or coupling phage treatments with surgical
procedures such as debridement. The model system of infection
is especially relevant here, because the details of escape may be
highly sensitive to the pathogen, host, and site of infection.
USE RELEVANT MODELS OF INFECTIONS
The empirical systems used to evaluate phages must mirror the
applications in which phages will be used. It is obviously conve-
nient to evaluate phages in vitro, but good phage performance in
culture medium can be a poor predictor of phage success in vivo
(e.g., Balogh et al., 2010; Tsonos et al., 2013b). In vitro relevance
may be enhanced with a system that mimics the in vivo environ-
ment closely: the culture of Staphylococcus aureus in a system of
native milk proteins showed strong inhibition of phage adsorp-
tion, even though the phage was able to aggressively control the
bacteria in broth culture (O’Flaherty et al., 2005; Gill et al., 2006).
Models that attempt to evaluate phages under more realistic con-
ditions may include ex vivo media (serum, blood, lymph, etc.),
tissue culture or bioﬁlm-promoting conditions. Even animalmod-
els may be misleading because they can behave differently than
natural infections found in patients (Bull et al., 2002; van der
Worp et al., 2010). Studies of phage dynamics in agricultural ani-
mal systems possesses a distinct beneﬁt here, as in these cases
the animal model is also the ultimate treatment target and the
experimental observationswill bemore directly related to practical
application.
MODELS
A new generation of models is needed, especially for dealing with
spatial heterogeneities. Parameterization of such models will not
likely be possible in vivo, but such models will nonetheless be
useful in identifying types of complexities that thwart treatment.
Once identiﬁed, those processes critical to dynamics may become
tractable for empirical study. At present in the absence of such
models, we have little idea what to look for. Such models may
need to be computational, as the analytic approximations required
to solve spatially structured equations do not lend themselves to
spatially varying parameter values.
CONCLUSION
The ﬁeld of phage therapy is ripe for approaches that explore
mechanisms underlying treatment success versus failure. We still
do not understand which phage properties are important to suc-
cess, whether those properties generalize across infection, and
whether dynamical superiority translates into treatment supe-
riority. At the optimistic end of the spectrum, we may hope
that the only important consideration for treatment is to use a
phage whose host range includes the infecting bacterium. The
pessimistic end of the spectrum is that no phages will work on
some bacteria. Between these extremes, there is a wealth of oppor-
tunity to discover how to make phage therapy a success by the
judicious exploitation of in vitro characterization, genomics, and
experiments in appropriately designed animal models.
ACKNOWLEDGMENTS
We thank Bruce Levin for helpful comments on the manuscript,
and Ian Molineux for years of discussion. Supported by NIH GM
57756 (James J. Bull), the Miescher Regents Professor (James J.
Bull), and Texas AgriLife Research (Jason J. Gill). We thank both
reviewers for their helpful clariﬁcations and suggested additions
to the paper.
REFERENCES
Abedon, S. (2011). Phage therapy pharmacology: calculating phage dosing. Adv.
Appl. Microbiol. 77, 1–40. doi: 10.1016/B978-0-12-387044-5.00001-7
Abedon, S. T. (2012). Spatial vulnerability: bacterial arrangements, microcolonies,
and bioﬁlms as responses to low rather than high phage densities. Viruses 4,
663–687. doi: 10.3390/v4050663
Abedon, S. T., Kuhl, S. J., Blasdel, B. G., and Kutter, E. M. (2011). Phage treatment
of human infections. Bacteriophage 1, 66–85. doi: 10.4161/bact.1.2.15845
Abedon, S. T., and Thomas-Abedon, C. (2010). Phage therapy pharmacology. Curr.
Pharm. Biotechnol. 11, 28–47. doi: 10.2174/138920110790725410
Adams, M. H. (1959). Bacteriophages. New York: Interscience Publishers.
Atterbury, R. J., Van Bergen, M. A. P., Ortiz, F., Lovel, M. A., Harris, J. A., De
Boer, A., et al. (2007). Bacteriophage therapy to reduce Salmonella colonization
of broiler chickens. Appl. Env. Microbiol. 73, 4543–4549. doi: 10.1128/AEM.
00049-07
Avery, O. T., and Dubos, R. (1931). The protective action of a speciﬁc enzyme
against type III Pneumococcus infection in mice. J. Exp. Med. 54, 73–89. doi:
10.1084/jem.54.1.73
Azeredo, J., and Sutherland, I. W. (2008). The use of phages for the removal
of infectious bioﬁlms. Curr. Pharm. Biotechnol. 9, 261–266. doi: 10.2174/
138920108785161604
Balogh, B., Jones, J. B., Iriarte, F. B., and Momol, M. T. (2010). Phage therapy
for plant disease control. Curr. Pharm. Biotechnol. 11, 48–57. doi: 10.2174/
138920110790725302
Barman, T. K., Rao, M., Bhati, A., Kishore, K., Shukla, G., Kumar, M., et al. (2011).
Non invasive real-time monitoring of bacterial infection and therapeutic effect
of anti-microbials in ﬁve mouse models. Indian J. Med. Res. 134, 688–695. doi:
10.4103/0971-5916.90997
Barr, J. J., Auroa, R., Furlana, M., Whitesona, K. L., Erbb, M. L., Poglianob, J., et al.
(2013). Bacteriophage adhering to mucus provide a non-host-derived immunity.
Proc. Natl. Acad. Sci. U.S.A. 110, 10771–10776. doi: 10.1073/pnas.1305923110
Bedi, M. S., Verma, V., and Chhibber, S. (2009). Amoxicillin and speciﬁc bacterio-
phage can be used together for eradication of bioﬁlm of Klebsiella pneumoniae
B5055. World J. Microbiol. Biotechnol. 25, 1145–1151. doi: 10.1007/s11274-009-
9991-8
Bull, J. J., Levin, B R., DeRouin, T., Walker, N., and Bloch, C. A., (2002). Dynamics
of success and failure in phage and antibiotic therapy in experimental infections.
BMC Microbiol. 2:35. doi: 10.1186/1471-2180-2-35
Bull, J. J., Millstein, J., Orcutt, J., and Wichman, H. A. (2006). Evolutionary feedback
mediated through population density, illustrated with viruses in chemostats. Am.
Nat. 167, E39–E51. doi: 10.1086/499374
Bull, J. J., Otto, G., and Molineux, I. J. (2012). In vivo growth rates are poorly
correlated with phage therapy success in a mouse infection model. Antimicrob.
Agents Chemother. 56, 949–954. doi: 10.1128/AAC.05842-11
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy November 2014 | Volume 5 | Article 618 | 10
Bull and Gill Phage properties for effective therapy
Bull, J. J., and Regoes, R. R. (2006). Pharmacodynamics of non-replicating
viruses, bacteriocins and lysins. Proc. Biol. Sci. 273, 2703–2712. doi:
10.1098/rspb.2006.3640
Bull, J. J., Vegge, C. S., Schmerer, M., Chaudhry, W. N., and Levin, B. R. (2014).
Phenotypic resistance and the dynamics of bacterial escape from phage control.
PLoS ONE 9:e94690. doi: 10.1371/journal.pone.0094690
Bull, J. J., Vimr, E. R., and Molineux, I. J. (2010). A tale of tails: sialidase is key
to success in a model of phage therapy against K1-capsulated Escherichia coli.
Virology 398, 79–86. doi: 10.1016/j.virol.2009.11.040
Campbell, A. (1961). Conditions for the existence of bacteriophage. Evolution 15,
143–165. doi: 10.2307/2406076
Capparelli, R., Nocerino, N., Lanzetta, R., Silipo, A., Amoresano, A., Giangrande,
C., et al. (2010a). Bacteriophage-resistant Staphylococcus aureus mutant confers
broad immunity against staphylococcal infection in mice. PLoS ONE 5:e11720.
doi: 10.1371/journal.pone.0011720
Capparelli, R., Nocerino, N., Iannaccone, M., Ercolini, D., Parlato, M., Chiara, M.,
et al. (2010b). Bacteriophage therapy of Salmonella enterica: a fresh appraisal of
bacteriophage therapy. J. Infect. Dis. 201, 52–61. doi: 10.1086/648478
Chan, B. K., andAbedon, S. T. (2012). Phage therapy pharmacology phage cocktails.
Adv. Appl. Microbiol. 78, 1–23. doi: 10.1016/B978-0-12-394805-2.00001-4
Chan, B. K., Abedon, S. T., and Loc-Carrillo, C. (2013). Phage cocktails and the
future of phage therapy. Future Microbiol. 8, 769–783. doi: 10.2217/fmb.13.47
Chhibber, S., Kaur, T., and Kaur, S. (2013). Co-therapy using lytic bacteriophage
and linezolid: effective treatment in eliminating methicillin resistant Staphylo-
coccus aureus (MRSA) from diabetic foot infections. PLoS ONE 8:e56022. doi:
10.1371/journal.pone.0056022
Contag, P. R. (2008). Bioluminescence imaging to evaluate infections and host
response in vivo. Methods Mol. Biol. 415, 101–118. doi: 10.1007/978-1-59745-
570-1_6
Edgar, R., Friedman, N., Molshanski-Mor, S., and Qimron, U. (2012). Revers-
ing bacterial resistance to antibiotics by phage-mediated delivery of dominant
sensitive genes. Appl. Environ. Microbiol. 78, 744–751. doi: 10.1128/AEM.057
41–5711
El-Shibiny, A., Scott, A., Timms, A., Metawea, Y., Connerton, P., and Connerton, I.
(2009). Application of a group IICampylobacter bacteriophage to reduce strains of
Campylobacter jejuni and Campylobacter coli colonizing broiler chickens. J. Food
Prot. 72, 733–740.
Francis, T., Terrell, E. E., Dubos, R., and Avery, O. T. (1934). Experimental type
III Pneumococcus pneumonia in monkeys: II. Treatment with an enzyme which
decomposes the polysaccharide of Pneumococcus type III. J. Exp. Med. 59, 641–
667. doi: 10.1084/jem.59.5.641
Gill, J. J. (2008). “Modeling of Bacteriophage Therapy,” in Bacteriophage Ecology:
Population Growth, Evolution, and Impact of Bacterial Viruses, ed. S. T. Abedon
(Cambridge: Cambridge University Press), 508.
Gill, J. J. (2010). “Practical and theoretical considerations for the use of bacterio-
phages in food systems,” in: Bacteriophages in the Control of Food- andWaterborne
Pathogens, eds P. M. Sabour and M. W. Grifﬁths (Washington, DC: ASM Press),
217–235. doi: 10.1128/9781555816629.ch11
Gill, J. J., and Hyman, P. (2010). Phage choice, isolation, and preparation for
phage therapy. Curr. Pharm. Biotechnol. 11, 2–14. doi: 10.2174/1389201107907
25311
Gill, J. J., Sabour, P. M., Leslie, K. E., and Grifﬁths, M. W. (2006). Bovine
whey proteins inhibit the interaction of Staphylococcus aureus and bacterio-
phage K. J. Appl. Microbiol. 101, 377–386. doi: 10.1111/j.1365-2672.2006.
02918.x
Gill, J. J., and Young, R. F. (2011). “Therapeutic applications of phage biology:
history, practice, and recommendations,” in Emerging Trends in An- tibacterial
Discovery: Answering the Call to Arms, eds A. A. Miller and P. F. Miller (Norfolk:
Caister Academic Press), 367–410.
Gladstone, E. G., Molineux, I. J., and Bull, J. J. (2012). Evolutionary principles
and synthetic biology: avoiding a molecular tragedy of the commons with an
engineered phage. J. Biol. Eng. 6, 13. doi: 10.1186/1754-1611-6-13
Goodridge, L. D. (2010). Designing phage therapeutics. Curr. Pharm. Biotechnol.
11, 15–27. doi: 10.2174/138920110790725348
Hadas, H., Einav, M., Fishov, I., and Zaritsky, A. (1997). Bacteriophage T4 develop-
ment depends on the physiology of its host Escherichia coli. Microbiology 143(Pt
1), 179–185. doi: 10.1099/00221287-143-1-179
Hagens, S., Habel, A., von Ahsen, U., von Gabain, A., and Bläsi, U. (2004).
Therapy of experimental Pseudomonas infections with a nonreplicating genet-
ically modiﬁed phage. Antimicrob. Agents Chemother. 48, 3817–3822. doi:
10.1128/AAC.48.10.3817-3822.2004
Harvey, P. H., and Purvis, A. (1991). Comparative methods for explaining
adaptations. Nature 351, 619–624. doi: 10.1038/351619a0
Henry, M., Lavigne, R., and Debarbieux, L. (2013). Predicting in vivo efﬁcacy
of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob.
Agents Chemother. 57, 5961–5968. doi: 10.1128/AAC.01596-13
Huff, W. E., Huff, G. R., Rath, N. C., Balog, J. M., and Donoghue, A. M. (2004).
Therapeutic efﬁcacy of bacteriophage and Baytril (enroﬂoxacin) individually and
in combination to treat colibacillosis in broilers. Poult. Sci. 83, 1944–1947. doi:
10.1093/ps/83.12.1944
Hughes, K. A., Sutherland, I. W., and Jones, M. V. (1998). Bioﬁlm sus-
ceptibility to bacteriophage attack: the role of phage-borne polysaccharide
depolymerase. Microbiology 144 (Pt 11), 3039–3047. doi: 10.1099/00221287-144-
11-3039
Hurley, A., Maurer, J. J., and Lee, M. D. (2008). Using bacteriophages to modulate
Salmonella colonization of the chicken’s gastrointestinal tract: lessons learned
from in silico and in vivo modeling. Avian. Dis. 52, 599–607. doi: 10.1637/8288-
031808-Reg.1
Levin, B. R., and Bull, J. J. (1996). Phage therapy revisited: the population biology
of a bacterial infection and its treatment with bacteriophage and antibiotics. Am.
Nat. 147, 881–898. doi: 10.1086/285884
Levin, B. R., and Bull, J. J. (2004). Population and evolutionary dynamics of phage
therapy. Nat. Rev. Microbiol. 2, 166–173. doi: 10.1038/nrmicro822
Levin, B. R., Stewart, F. M., and Chao, L. (1977). Resource - limited growth, com-
petition , and predation: a model and experimental studies with bacteria and
bacteriophage. Am. Nat. 977, 3–24. doi: 10.1086/283134
Lu, T. K., and Collins, J. J. (2007). Dispersing bioﬁlms with engineered enzy-
matic bacteriophage. Proc. Natl. Acad. Sci. U.S.A. 104, 11197–11202. doi:
10.1073/pnas.0704624104
Lu, T. K., andCollins, J. J. (2009). Engineered bacteriophage targeting gene networks
as adjuvants for antibiotic therapy. Proc. Natl. Acad. Sci. U.S.A. 106, 4629–4634.
doi: 10.1073/pnas.0800442106
Malnoy, M., Faize, M.,Venisse, J.-S., Geider, K., and Chevreau, E. (2005). Expression
of viral EPS-depolymerase reduces ﬁre blight susceptibility in transgenic pear.
Plant Cell Rep. 23, 632–638. doi: 10.1007/s00299-004-0855-2
Matsuda, T., Freeman, T. A., Hilbert, D. W., Duff, M., Fuortes, M., Stapleton, P.
P., et al. (2005). Lysis-deﬁcient bacteriophage therapy decreases endotoxin and
inﬂammatory mediator release and improves survival in a murine peritonitis
model. Surgery 137, 639–646. doi: 10.1016/j.surg.2005.02.012
Matsuzaki, S., Yasuda, M., Nishikawa, H., Kuroda, M., Ujihara, T., Shuin, T., et al.
(2003). Experimental protection of mice against lethal Staphylococcus aureus
infection by novel bacteriophage phi MR11. J. Infect. Dis. 187, 613–624. doi:
10.1086/374001
Merril, C. R., Biswas, B., Carlton, R., Jensen, N. C., Creed, G. J., Zullo, S., et al.
(1996). Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad.
Sci. U.S.A. 93, 3188–3192. doi: 10.1073/pnas.93.8.3188
Moldovan, R., Chapman-Mcquiston, E., and Wu, X. L. (2007). On kinetics of phage
adsorption. Biophys. J. 93, 303–315. doi: 10.1529/biophysj.106.102962
Mushtaq, N., Redpath, M. B., Luzio, J. P., and Taylor, P. W. (2004). Preven-
tion and cure of systemic Escherichia coli K1 infection by modiﬁcation of
the bacterial phenotype. Antimicrob. Agents Chemother. 48, 1503–1508. doi:
10.1128/AAC.48.5.1503-1508.2004
O’Flaherty, S., Coffey,A.,Meaney,W. J., Fitzgerald, G. F., andRoss, R. P. (2005). Inhi-
bition of bacteriophage K proliferation on Staphylococcus aureus in raw bovine
milk. Lett. Appl. Microbiol. 41, 274–279. doi: 10.1111/j.1472-765X.2005.01762.x
Pagel, M. D., and Harvey, P. H. (1988). Recent developments in the analysis of
comparative data. Q. Rev. Biol. 63, 413–440. doi: 10.1086/416027
Paul, V. D., Sundarrajan, U., Rajagopalan, S. S., Hariharan, S., Kempashanaiah, N.,
Padmanabhan, S., et al. (2011). Lysis-deﬁcient phages as novel therapeutic agents
for controlling bacterial infection. BMC Microbiol. 11:195. doi: 10.1186/1471-
2180-11-195
Payne, R. J., and Jansen, V. A. (2001). Understanding bacteriophage ther-
apy as a density-dependent kinetic process. J. Theor. Biol. 208, 37–48. doi:
10.1006/jtbi.2000.2198
www.frontiersin.org November 2014 | Volume 5 | Article 618 | 11
Bull and Gill Phage properties for effective therapy
Payne, R. J. H., and Jansen, V. A. A. (2003). Pharmacokinetic principles of bac-
teriophage therapy. Clin. Pharmacokinet. 42, 315–325. doi: 10.2165/00003088-
200342040-00002
Peng, Y., Jin, Y., Lin, H., Wang, J., and Khan, M. N. (2014). Application of
the VPp1 bacteriophage combined with a coupled enzyme system in the rapid
detection of Vibrio parahaemolyticus. J. Microbiol. Methods. 98, 99–104. doi:
10.1016/j.mimet.2014.01.005
Rahman, M., Kim, S., Kim, S. M., Seol, S. Y., and Kim, J. (2011). Characterization of
induced Staphylococcus aureus bacteriophage SAP-26 and its anti-bioﬁlmactivity
with rifampicin. Biofouling 27, 1087–1093. doi: 10.1080/08927014.2011.631169
Ryan, E. M., Gorman, S. P., Donnelly, R. F., and Gilmore, B. F. (2011). Recent
advances in bacteriophage therapy: how delivery routes, formulation, concentra-
tion and timing inﬂuence the success of phage therapy. J. Pharm. Pharmacol. 63,
1253–1264. doi: 10.1111/j.2042-7158.2011.01324.x
Schmerer,M.,Molineux, I. J., Ally, D., Tyerman, J., Cecchini, N., and Bull, J. J. (2014).
Challenges in predicting the evolutionary maintenance of a phage transgene.
J. Biol. Eng. 8, 21. doi: 10.1186/1754-1611-8-21
Schoﬁeld, D., Bull, C. T., Rubio, I., Wechter, W. P., Westwater, C., Molineux, I. J.,
et al. (2013). ‘Light-tagged’ bacteriophage as a diagnostic tool for the detection of
phytopathogens. Bioengineered 4, 50–54. doi: 10.4161/bioe.22159
Scholl, D., Adhya, S., and Merril, C. (2005). Escherichia coli K1’s capsule is a
barrier to bacteriophage T7. Appl. Environ. Microbiol. 71, 4872–4874. doi:
10.1128/AEM.71.8.4872-4874.2005
Scott, A. E., Timms, A. R., Connerton, P. L., El-Shibiny, A., and Connerton,
I. F. (2007). Bacteriophage inﬂuence Campylobacter jejuni types populating
broiler chickens. Environ. Microbiol. 9, 2341–2353. doi: 10.1111/j.1462-
2920.2007.01351.x
Smith, H. W., and Huggins, M. B. (1982). Successful treatment of experimen-
tal Escherichia coli infections in mice using phage: its general superiority over
antibiotics. J. Gen. Microbiol. 128, 307–318.
Sutherland, I. W. (1995). Polysaccharide lyases. FEMS Microbiol. Rev. 16, 323–347.
doi: 10.1111/j.1574-6976.1995.tb00179.x
Tsonos, J., Vandenheuvel, D., Briers, Y., De Greve, H., Hernalsteens, J. P., Lavigne, R.,
et al. (2013a). Hurdles in bacteriophage therapy: deconstructing the parameters.
Vet. Microbiol. 171, 460–469. doi: 10.1016/j.vetmic.2013.11.001
Tsonos, J., Oosterik, L. H., Tuntufye, H. N., Klumpp, J., Butaye, P., De Greve, H.,
et al. (2013b). A cocktail of in vitro efﬁcient phages is not a guarantee for in vivo
therapeutic results against avian colibacillosis. Vet. Microbiol. 171, 470–479. doi:
10.1016/j.vetmic.2013.10.021
van der Worp, H. B., Howells, D. W., Sena, E. S., Porritt, M. J., Rewell, S., O’Collins,
V., et al. (2010). Can animal models of disease reliably inform human studies?
PLoS Med. 7:e1000245. doi: 10.1371/journal.pmed.1000245
Verma, V., Harjai, K., and Chhibber, S. (2009). Restricting ciproﬂoxacin-induced
resistant variant formation in bioﬁlm of Klebsiella pneumoniae B5055 by comple-
mentary bacteriophage treatment. J. Antimicrob. Chemother. 64, 1212–1218. doi:
10.1093/jac/dkp360
Verma, V., Harjai, K., and Chhibber, S. (2010). Structural changes induced by a
lytic bacteriophage make ciproﬂoxacin effective against older bioﬁlm of Klebsiella
pneumoniae. Biofouling 26, 729–737. doi: 10.1080/08927014.2010.511196
Viertel, T. M., Ritter, K., and Horz, H.-P. (2014). Viruses versus bacteria-novel
approaches to phage therapy as a tool against multidrug-resistant pathogens.
J. Antimicrob. Chemother. 69, 2326–2336. doi: 10.1093/jac/dku173
Weld, R. J., Butts, C., and Heinemann, J. A. (2004). Models of phage growth and
their applicability to phage therapy. J. Theor. Biol. 227, 1–11. doi: 10.1016/S0022-
5193(03)00262-5
Westwater, C., Kasman, L. M., Schoﬁeld, D. A., Werner, P. A., Dolan, J.
W., Schmidt, M. G., et al. (2003). Use of genetically engineered phage to
deliver antimicrobial agents to bacteria: an alternative therapy for treatment
of bacterial infections. Antimicrob. Agents Chemother. 47, 1301–1307. doi:
10.1128/AAC.47.4.1301-1307.2003
Conflict of Interest Statement: The authors declare that the researchwas conducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 10 July 2014; accepted: 30 October 2014; published online: 18 November
2014.
Citation: Bull JJ and Gill JJ (2014) The habits of highly effective phages: population
dynamics as a framework for identifying therapeutic phages. Front. Microbiol. 5:618.
doi: 10.3389/fmicb.2014.00618
This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section
of the journal Frontiers in Microbiology.
Copyright © 2014 Bull and Gill. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy November 2014 | Volume 5 | Article 618 | 12
